Amgen Ends TScan Therapeutics Collaboration, Effective November 10
TCRX sits 16% above its 52-week low of $0.716 on light trading volume (0.3× avg).
Summary
Amgen is terminating its research collaboration and license agreement with TScan Therapeutics, effective November 10, 2026. The SEC filing does not disclose the reason or financial terms. For TScan, a small-cap partner, losing a major pharma collaborator removes a key validation and potential milestone revenue stream. For Amgen, the impact is modest given its $230B market cap, but it signals a strategic shift away from this program. Watch for TScan's response and any disclosed termination fees or pipeline implications.
At the time of this announcement, TCRX was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.9M. The 52-week trading range was $0.72 to $2.57. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.